Cannabis Bioscience International Holdings

What Cannabis Bioscience International Holdings does

Cannabis Bioscience International Holdings, Inc. (OTC: CBIH) is a Houston-based, publicly traded cannabinoid life sciences company operating across clinical research, education, and consumer wellness. The company is structured around three operating assets: Alpha Research Institute, LLC, a wholly owned clinical research unit offering phase I–IV studies and citing prior engagements with Pfizer, Philip Morris, Inventiva, and Biovt; Pharmacology University, an international education and content platform publishing ebooks, audiobooks, videos, and magazines on cannabinoid medicine via Amazon Kindle, Audible, Kobo, Barnes & Noble, Google Books, and Scribd; and VitaCookies, a functional wellness cookie brand formulated with cannabinoid and nutritional ingredients for menopause support, stress management, and mental well-being. The underlying technology is a proprietary nanoemulsion delivery platform, with patent-pending or filed applications covering an intranasal system for Alzheimer's research, a fertility formulation for women over 35, an endocannabinoid-based opioid addiction therapy, and a cannabinoid-plus-psilocybin PTSD research framework.

CBIH's go-to-market combines licensed-operator brand distribution for VitaCookies (initial operator NCAS, LLC in Dallas and Houston), direct-to-consumer hemp product manufacturing under its Texas state license (approved July 2026), professional-services revenue from clinical research contracts, and subscription/educational content via Pharmacology University. Capital is raised primarily through a Regulation A equity offering at a $0.00018 share price with a $2,000 minimum. The company is also participating in DEA administrative hearings on federal marijuana rescheduling from Schedule I to Schedule III, positioning itself for potential regulatory tailwinds.

The business model remains pre-commercial at scale: no revenue is disclosed, headcount is 1–10 employees, and the VitaCookies launch via NCAS is the first commercial licensing agreement. The core near-term commercial bet is that VitaCookies licensing in Texas (and potentially Mexico City) and clinical research contracts will generate cash flow to fund the longer-dated, higher-risk therapeutic patent portfolio targeting Alzheimer's, opioid addiction, fertility, and PTSD.

Name

Cannabis Bioscience International Holdings

Legal name

Cannabis Bioscience International Holdings, Inc.

Website

https://cbih.net

Company type

Public

Founded year

2003

Operating status

Operating

Headcount range

1–10 employees

Short description

Cannabis Bioscience International Holdings (CBIH) is a Houston-based publicly traded cannabinoid life sciences company operating Alpha Research Institute for clinical trials, Pharmacology University for cannabinoid education, and the VitaCookies wellness brand distributed via licensed operators in Texas.

Ownership category

akta.pro rank

Product category

Medical Cannabis Research and Therapeutics

NAICS

Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

CBD/Hemp Wellness & Supplements Retail (CRANAHAC)

akta.pro secondary industry

Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services) (CRANAFAI)

Keywords

• Cannabinoid clinical research
• Medical cannabis therapeutics
• Hemp consumer products
• Pharmaceutical research services
• Cannabis education platform

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. VitaCookies Brand Licensing: CBIH licenses its VitaCookies brand to authorized operators like NCAS LLC, generating revenue through licensing agreements while maintaining brand control and testing market response through Dallas and Houston locations.
2. Consumable Hemp Products Manufacturing and Distribution: Following Texas license approval, CBIH manufactures and distributes consumable hemp products including functional wellness cookies targeting menopause support, stress management, and relaxation categories.
3. Clinical Research Services: Alpha Research Institute, LLC provides phase I to phase IV clinical research studies as a revenue stream, with collaborations with pharmaceutical companies including Biovt, Phillips Morris, Pfizer, and Inventiva.
4. Education and Knowledge Platform: CBIH operates Pharmacology University, an international learning platform providing knowledge about cannabinoids' medical benefits through ebooks, audiobooks, videos, and magazines.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Cannabis Bioscience International Holdings (CBIH) is a cannabinoid-focused healthcare holding company that operates clinical research services through its Alpha Research Institute subsidiary (Phase I-IV clinical trials), an international cannabinoid education platform called Pharmacology University, and a consumer wellness product line (VitaCookies) under its Texas consumable hemp license. The company develops proprietary nanoemulsion delivery platforms and patent-pending cannabinoid formulations targeting Alzheimer's disease, female fertility, PTSD, and opioid addiction.

Product overview

CBIH operates as a multi-divisional cannabinoid healthcare company combining clinical research, education, and consumer products. The core research operations are conducted through Alpha Research Institute, LLC (a Houston-based phase I-IV clinical research unit), while Pharmacology University serves as the international education and publication platform. Consumer-facing products center on VitaCookies, a functional wellness cookie line, with multiple novel delivery platforms under development including intranasal nanoemulsion for Alzheimer's, fertility nanoemulsion formulations, and cannabinoid/psilocybin research programs for PTSD and opioid addiction.

Differentiator

Problem solved

Functional benefit

Brands

• VitaCookies: Functional wellness cookie line formulated with cannabinoid and nutritional ingredients targeting menopause support, stress management, and mental well-being categories.

Products and services

• VitaCookies Functional wellness cookie line formulated with cannabinoid and nutritional ingredients targeting menopause support, stress management, and mental well-being categories. Distributed through Texas-licensed operators under brand licensing agreements.
• Alpha Research Institute, LLC Houston-based clinical research unit offering Phase I to Phase IV clinical research studies across therapeutic areas. Has conducted research for pharmaceutical companies including Biovt, Phillips Morris, Pfizer, and Inventiva.
• Pharmacology University International learning platform providing knowledge about cannabinoids' medical benefits through ebooks, audiobooks, videos, and magazines, drawing on more than 15 years of research. Partners with institutions including Universidad Tadeo Bello for cannabis education programs.
• Intranasal Nanoemulsion Platform for Alzheimer's Research Proprietary intranasal nanoemulsion platform designed for cannabinoid-based and natural compound delivery targeting Alzheimer's disease research, utilizing a multi-pathway approach to neurodegenerative conditions rather than targeting single biological pathways.
• Fertility Nanoemulsion Formulation Patent-pending nanoemulsion formulation leveraging cannabinoids and bioactives to support female fertility in women over 35, targeting age-related reproductive decline and improving outcomes in assisted reproductive technologies.
• Cannabinoid and Psilocybin PTSD Research Program Patent-related scientific framework for PTSD-focused research involving cannabinoids and psilocybin, addressing trauma biology dimensions including stress response, neuroplasticity, and emotional regulation.
• Opioid Addiction Endocannabinoid Therapy Investigational therapy targeting opioid addiction through brain reward circuits and the endocannabinoid system, designed to support recovery and reduce relapse rates in opioid use disorder.

Quantifiable outcome

• Targeting 13 million Americans with PTSD
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• NCAS, LLCcoreOEM/ Whitelabel/ Licensing Partner · 22 June 2026CBIH signed its first commercial licensing agreement for the VitaCookies brand with NCAS, LLC, a Dallas-based operator. NCAS serves as the initial authorized operator, with CBIH planning brand-building efforts at VitaCookies Dallas and VitaCookies Houston locations. CBIH and NCAS are evaluating Mexico City as a potential future international entry point for the brand. The agreement establishes NCAS as the initial authorized operator while giving CBIH a controlled pathway to monetize VitaCookies as a scalable commercial asset.
• Brian CubanminorOthers · 26 February 2024Brian Cuban joined CBIH as an Advisory Board Member, bringing decades of experience in legal and corporate leadership and a track record of coaching diverse professionals around the world.
• Alpha Research Institute, LLCcoreStrategic or Co-development PartnerAlpha Research Institute, LLC is a Houston-based Research Unit that offers phase I to phase IV Clinical Research Studies. It operates as a core subsidiary of CBIH providing clinical research capabilities. Some companies Alpha Research Institute has worked with in research phases include Biovt, Phillips Morris, Pfizer, and Inventiva.
• Pharmacology UniversitycoreStrategic or Co-development PartnerAn international learning platform operated by CBIH that provides knowledge about cannabinoids' medical benefits. With over 15 years of research, Pharmacology University has published ebooks, audiobooks, videos, and magazines, and partners with institutions including Universidad Tadeo Bello for cannabis education programs.
• Biovt, Phillips Morris, Pfizer, InventivaminorStrategic or Co-development PartnerPharmaceutical companies that Alpha Research Institute has worked with in some of the research phases (phase I to phase IV).

Scale indicators7 records

Recent moves6 records

Expansion highlights3 records

Broad incumbents

• Canopy Growth Corporation: A major cannabis research, cultivation, and consumer products company pursuing both medical cannabis and pharmaceutical-grade cannabinoid products. Comparable for its research-plus-consumer diversification model and clinical research initiatives.
• Cronos Group: A vertically integrated cannabis company with consumer brands and cannabinoid research initiatives including novel formulations and delivery technologies. Comparable in pursuing both consumer and pharmaceutical-grade cannabinoid opportunities.
• Medical Marijuana Inc. A hemp-derived CBD products and cannabinoid wellness company with consumer brands, distribution, and research positioning. Comparable to CBIH's consumer and educational content strategy around CBD and minor cannabinoids.
• Tilray Brands: A large global cannabis and cannabinoid company with operations spanning medical cannabis, consumer products, and pharmaceutical-grade manufacturing. Comparable as a broad incumbent operating in research, consumer, and clinical channels that CBIH is attempting to address.
• GW Pharmaceuticals (now part of Jazz Pharmaceuticals): Pioneer in cannabinoid-based prescription medicines and developer of Epidiolex, the first FDA-approved CBD drug. Comparable as the gold-standard cannabinoid pharmaceutical researcher and the benchmark CBIH's clinical and IP strategy implicitly targets.
• Aphria / Aurora Cannabis: Large medical and recreational cannabis producers with research arms developing cannabinoid-based therapeutic products. Comparable as a broad incumbent cannabis research and consumer-products company.

Direct peers

• Zynerba Pharmaceuticals (now Vyne Therapeutics): A specialty pharmaceutical company developing cannabinoid-based transdermal therapeutics for rare neurological and developmental disorders. Highly comparable as a small-cap, clinically-focused cannabinoid drug developer pursuing multiple therapeutic indications using proprietary delivery technology.
• Charlotte's Web Holdings: A CBD wellness company offering hemp-derived cannabinoid products including ingestibles and topicals for sleep, stress, and recovery. Directly comparable to CBIH's VitaCookies wellness consumer line and similar multi-channel distribution model.
• Tetra Bio-Pharma: A cannabinoid-based drug development company focused on prescription medicines for pain, inflammation, and oncology. Comparable as a clinical-stage cannabinoid pharmaceutical developer pursuing FDA pathways and patent-protected formulations.

Emerging players

• AXIM Biotechnologies: A research-stage cannabinoid pharmaceutical company developing treatments for multiple sclerosis, pain, and other conditions. Comparable as a small-cap, IP-driven cannabinoid drug developer pursuing similar therapeutic indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/cbihstock
• Instagraminstagram.com/CBIHSTOCK

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cannabis Bioscience International Holdings